Clinical trial
Phase II Trial of Allovectin-7® for Metastatic Melanoma
NCT00044356 · Vical, Industry · Completed
Key facts
| NCT number | NCT00044356 |
|---|---|
| Title | Phase II Trial of Allovectin-7® for Metastatic Melanoma |
| Official title | A Phase II Study of High-Dose Allovectin-7® in Patients With Advanced Metastatic Melanoma |
| Lead sponsor | Vical, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma, Metastatic Melanoma, Malignant Melanoma, Skin Cancer |
| Intervention type | Genetic |
| Interventions | Allovectin-7® |
| Enrollment | 133 |
| Start date | Feb 1, 2001 |
| Primary completion | Aug 1, 2004 |
| Completion | Sep 1, 2004 |
| First posted | Aug 28, 2002 |
| Last update posted | Jul 7, 2011 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: